<DOC>
	<DOCNO>NCT01640873</DOCNO>
	<brief_summary>This study assess initial safety , tolerability , pharmacokinetics , pharmacodynamics MK-8655 , single multiple daily oral administration participant Type 2 Diabetes ( T2DM ) . The study assess reduction fast plasma glucose concentration baseline multiple daily administration MK-8655 .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics MK-8655 Participants With Type 2 Diabetes ( MK-8655-002 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female nonchild bear potential Body Mass Index â‰¤40 kg/m^2 Diagnosis Type 2 Diabetes ( T2DM ) either drug naive treat metformin In good health except T2DM Willing follow standard diet Nonsmoker and/or use nicotine nicotinecontaining product 6 month Mentally legally incapacitate History stroke , chronic seizure , major neurological disorder History clinically significant endocrine ( except T2DM ) , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases History neoplastic myeloproliferative disease Has clinical unstable rapidly progress diabetic retinopathy , neuropathy , and/or frequent nausea , bloat vomiting , severe gastroesophageal reflux early satiety Has history Type 1 Diabetes and/or history ketoacidosis Use lipidlowering therapy past 3 month Nonpermitted medication comorbid condition Excessive alcohol caffeine use Participation another investigational study within 4 week prior study A history significant multiple and/or severe allergy anaphylactic reaction Regular user illicit drug history alcohol abuse within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 2 Diabetes</keyword>
</DOC>